Comparison of the tumor immune microenvironment phenotypes in different breast cancers after neoadjuvant therapy

Neoadjuvant therapy (NAT) treats early‐stage breast cancers, especially triple‐negative breast cancers (TNBCs). NAT improves pathological complete response (pCR) rates for different breast cancer patients. Recently, immune checkpoint inhibitors that target programmed death 1 (PD‐1) or programmed dea...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Mengxue, Li, Jinze, Wu, Si, Wu, Chun, Yu, Yongqiang, Liu, Yueping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939127/
https://www.ncbi.nlm.nih.gov/pubmed/36073303
http://dx.doi.org/10.1002/cam4.5207

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939127/
https://www.ncbi.nlm.nih.gov/pubmed/36073303
http://dx.doi.org/10.1002/cam4.5207

Ejemplares similares